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Recently the paradigm that the healthy lung is sterile was challenged and it is now
believed that the lungs harbor a diverse microbiota also contributing to the pathogenesis
of various diseases. Most of the research studies targeting the respiratory microbiome
have focused on bacteria and their impact on lung health and lung diseases. Recently,
also the mycobiome has gained attention. Lower respiratory tract (LRT) diseases (e.g.,
cystic fibrosis) and other diseases or conditions (e.g., HIV infection, lung transplantation,
and treatment at intensive care units) have been investigated with regard to possible
involvement of mycobiome in development or progression of diseases. It has been
shown that diversities of mycobiome in the LRT vary in different populations and
conditions. It has been proposed that the mycobiome diversity associated with LRT can
vary with different stages of diseases. Overall, Candida was the dominant fungal genus
in LRT samples. In this review, we summarize the recent findings regarding the human
LRT mycobiome from a clinical perspective focussing on characterization of investigated
patient groups and healthy controls as well as sampling techniques. From these data,
clinical implications for further studies or routine practice are drawn. To obtain clinically
relevant answers efforts should be enhanced to collect well characterized and described
patient groups as well as healthy individuals for comparative data analysis and to apply
thorough sampling techniques. We need to proceed with elucidation of the role of
mycobiota in healthy LRT and LRT diseases to hopefully improve patient care.
Keywords: mycobiome, lower respiratory tract, Candida, cystic fibrosis, intensive care unit
INTRODUCTION
The lower respiratory tract (LRT) includes airways distal of the vocal cords, i.e., trachea, bronchi,
bronchioles and anatomical structures of the lung, i.e., respiratory bronchioles, alveolar ducts,
alveolar sacs, and alveoli (Schönbach, 2013). Fungal diseases affecting the LRT comprise invasive
fungal infections (IFI) and diseases triggered by fungal LRT colonization or inhalation (e.g., allergic
bronchopulmonary aspergillosis). Some respiratory diseases are possibly associated with fungal
colonization, i.e., exacerbation of chronic obstructive pulmonary disease (COPD) or deterioration
of lung function and structure in cystic fibrosis (CF) patients (Nguyen et al., 2015). Candida is often
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cultured from LRT samples but the clinical significance is
still unknown. Baum (1960) started a discussion regarding the
significance of Candida in the LRT by presenting data from
conventional microbiological investigations of LRT samples. He
described that the source of Candida present in the sputum
samples was the mouth and that little significance could be
attached to the finding of Candida within the sputum in
the diagnosis of pulmonary candidiasis. Since then subsequent
culture based studies investigating Candida in the LRT have
given conflicting results (Corley et al., 1997; el-Ebiary et al., 1997;
Eggimann et al., 2003; Meersseman et al., 2009).
In general, cultivation-independent molecular assays are more
efficient in describing microbial communities than culture-
based approaches which fail to detect the whole diversity of
a microbiota and, therefore, hinder complete understanding
of the interactions between the host and the microbiome
(Ghannoum et al., 2010; Bittinger et al., 2014; Nguyen et al.,
2015). However, compared to bacterial microbiota investigation
surveys on the mycobiota of the LRT are still rare. Performing
a literature search via PubMed 86 hits are generated by using
“mycobiome” as a search term, 9 using “lung mycobiome” and
10 using “respiratory mycobiome” (four of the publications
appear also in “lung mycobiome” search1; accessed November 21,
2016).
An overview of the current state of knowledge with
respect to concepts of LRT mycobiota, the association of
LRT mycobiota and fungal communities in other anatomical
regions of the human body as well as the role of LRT
mycobiota in some LRT diseases has been published recently
(Nguyen et al., 2015). In comparison, the LRT mycobiota
review presented here primarily addresses the characterization
of investigated patient groups and healthy controls as well
as utilized sampling techniques. From a clinical point of
view, thorough selection of patient groups together with clear
description of underlying diseases as well as antiinfective and
non-antiinfective treatments that might influence bacterial and
fungal microbiota are essential to detect relevant differences
in fungal communities. From that informations it might be
possible to draw clinically relevant conclusions and diagnostic
as well as therapeutic implications. Beside differences in patient
selection and molecular approaches, sampling techniques are also
relevant for interpretation of results. In this review we therefore
summarize recent literature addressing LRT mycobiome and
its potential role in respiratory disease in certain patient
groups and discuss the results from a clinical perspective
including the potential influences by sampling techniques
applied.
ORAL MYCOBIOME
Since LRT samples are commonly collected by procedures
wherein the oral cavity is passed, the composition of the
oral mycobiota is relevant to interpret LRT mycobiota studies.
Although fungal colonization of the oral cavity is not imperatively
1http://www.ncbi.nlm.nih.gov/pubmed/?term=mycobiome
connected to fungal colonization of other anatomical regions,
e.g., the intestinal tract (Zollner-Schwetz et al., 2008), the
contact of true LRT samples with saliva and/or mucosal
surfaces occurring during expectoration of e.g., sputum samples
might alter mycobiota composition in LRT samples. Oral
mycobiota were investigated in healthy individuals to provide
a basis for a detailed characterization of the oral mycobiome
in health and disease. With results of that study the term
mycobiome was introduced in medical literature as confirmed
by our mycobiome literature search in PubMed starting with
Ghannoum’s paper published in 2010 (Ghannoum et al., 2010).
In that study, oral rinse using 15 ml of phosphate buffered
saline was obtained from 20 healthy subjects (21–60 years
of age, eight females and 12 males; non-smoking, no recent
antifungal use, and no clinical signs of oral mucosal disease).
Exclusion criteria were a history of receiving medication or
treatment with topical or systemic steroids, pregnancy, and
a history of insulin-dependent diabetes mellitus. Internal
transcribed spacer (ITS) based sequencing revealed that the
oral cavity contained 74 cultivable (most abundant genera:
Candida, Cladosporium, Aureobasidium, Saccharomycetales)
and 11 non-cultivable fungal genera. The low-abundance
genera were considered to represent environmental fungi that
have been transferred into the oral cavity by inhalation of
spores or by ingesting fungal contaminated food (Ghannoum
et al., 2010). As only healthy individuals were investigated
the influence of antibacterial and antifungal therapy and
certain immunosuppressive conditions predisposing for
fungal infections (e.g., underlying diseases like hemato-
oncological malignancies, diabetes mellitus, intensive care unit
treatment, immunosuppressive treatments like corticosteroids,
cyclophosphamide, antineoplastic chemotherapy, biological
therapy) on oral mycobiota remain unknown. It should
be mentioned, however, that this study lacked appropriate
contamination controls and extraction blanks, thus the possible
introduction of fungal signatures by the used reagents cannot be
excluded.
MYCOBIOME OF CYSTIC FIBROSIS
PATIENTS
In one of the first papers presenting LRT mycobiome data, eight
sputum samples from four (two male and two female) adult CF
patients (range 19–39 years) were investigated by pyrosequencing
of ITS2 amplicons (Delhaes et al., 2012). For assessment of
fungal and bacterial interaction 16S rRNA gene sequencing
was included. Two temporal sputum samples were collected
from each clinically stable patient with a sampling interval
of 1 year, but in one patient the sampling interval was only
3 months. Samples were collected by expectoration into a sterile
cup after a water rinse. Two patients received azithromycin due
to Pseudomonas colonization and other unspecified antibiotic
therapies (two courses in one patient and up to seven courses
in the second patient previous to the first sputum sample).
Three patients had inhalative and one patient had additional
systemic corticosteroid therapy. One patient was treated with
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itraconazole 600 mg for 183 days due to bronchopulmonary
allergic aspergillosis prior to sampling. Results showed high
molecular diversities for the main fungal and bacterial taxa
and high intra-individual differences as mycobiota changed
between the sampling time points (e.g., 202 Candida reads in
sample 1 and 8688 Candida reads in sample 2 in patient 1).
Anaerobes were isolated together with Pseudomonas aeruginosa,
and the latter was found more likely co-associated with Candida
albicans than with Aspergillus fumigatus. Aside of the bacterial
findings the authors concluded that the diversity and species
richness of fungal communities was significantly lower in patients
with decreased lung function and poor clinical status. It was
further mentioned that C. albicans and C. parapsilosis, as part
of the oral mycobiome, could migrate from the oral niche,
and colonize and persist within the lower airways of CF
patients. However, since Candida is the major genus found
in the oral cavity as shown in the oral mycobiota study
investigating healthy subjects mentioned above and since oral
mycobiota have not been investigated in this CF study these
conclusions must be interpreted with caution. It is not clear
from that CF study whether “sputum” samples represented
adequate sputum produced from the LRT and how the oral
mycobiota impacted the LRT sputum mycobiota. In addition, the
present CF cohort was small (four patients), included CF patients
with different treatments that might affect LRT mycobiota
(corticosteroids, antibiotics, and antimycotics), and lacked a
specific control group. The association of reduced diversity and
richness of fungal and bacterial microbiota with poor clinical
status and lung function (reduced FEV1 and FVC) was mainly
derived from two patients with preceding antibiotic therapy
and antifungal therapy. Therefore, influence of antiinfective
therapy on reduced microbial diversity and richness cannot
be ruled out and the association with lung function remains
questionable.
Another study encompassed six CF patients, which were
admitted for antibiotic therapy due to respiratory disease
exacerbation and Pseudomonas sp. positive sputum cultures.
ITS based mycobiota analysis was performed with sputum
samples collected from this cohort prior to and after systemic
antibiotic treatment (Willger et al., 2014). One patient received
tobramycin and meropenem; one tobramycin and ceftazidime;
one tobramycin, ceftazidime and linezolid; two tobramycin,
doripenem and vancomycin; and one tobramycin and
doripenem. Inhalative antibacterial therapy (as applied in
other CF cohorts as described below) was not mentioned
in the studied patients as well as information on preceding
antibacterial therapy was lacking. As CF patients repeatedly
receive antibacterial (and sometimes antifungal) therapy for
infectious exacerbation of underlying disease previous therapies
might have impacted the observed LRT mycobiota results.
In mycobiota analysis Candida represented the dominant
genus with 11 different species (top three were C. albicans,
C. dubliniensis, and C. parapsilosis) and accounted for 74–99.9%
of all ITS1 reads in all samples making these species both the
most abundant and also the most prevalent. However, there
was a broad distribution of C. albicans relative abundance
ranging from 0.1% of reads (post-treatment sample from
subject number 2) to 98.8% of reads (post-treatment sample
from subject number 6). Besides C. albicans only Malassezia
species occurred in all samples with 10- to 50-fold lower
reads compared to Candida species. Also non-fumigatus
Aspergillus species were detected at low levels. The relative
abundance of Candida species was stable during antibiotic
treatment and antibiotic treatment did not establish a specific
fungal community. Fungal density varied after completion of
antibiotic treatment with increase or decrease in individual
patients but no common trend could be observed. Overall, no
specific trend in fungal burden associated with antibacterial
therapy could be detected. In contrast to decreased bacterial
richness after antibacterial treatment no significant difference
was determined for fungal richness although a trend for
a decrease was observed. Candida and Malassezia species
accounted for more than 80% of all assigned reads per
sample and persisted throughout antibacterial treatment
without significant change in relative abundance suggesting
stability within the mycobiome. As with the other CF study,
it is not clear if “sputum” samples represented adequate
sputum produced from the LRT and if the oral mycobiota
contaminated and impacted presumed LRT sputum mycobiota.
For further clarification of the role of mycobiota in LRT
the authors also suggested methods to differentiate between
dead or alive microorganisms to assess active microbiota in
the LRT.
In another study 72 sputum samples were collected from
56 CF patients recruited in an ambulatory center including
a subcohort of 13 patients who provided sputum two (10
patients) or three (three patients) times within a 2-years
sampling period (Kramer et al., 2015a). Sputum samples were
collected in duplicate, stored at −20◦C and subsequently
analyzed by ITS primer based PCR, preparation of single
stranded DNA, single-strand conformation polymorphism
electrophoresis and sequencing of individual bands. C. albicans
and C. dubliniensis were the most dominant fungal species
in the CF cohort, with 44.4% and 23.6% positive samples,
respectively, followed by Saccharomyces cerevisiae, with
19.4%, and C. parapsilosis, with 13.8% positive samples.
Several other fungi were detected at lower rates including
Aspergillus sp., and Cladosporium sp., Scedosporium and
Exophiala sp. In patients investigated at two time points different
fungi were detected in the same patient indicating dynamic
mycobiota composition. In concordance with the other CF
study mentioned above it is not clear from this particular
CF study if “sputum” samples represented adequate sputum
produced from the LRT and how oral mycobiota impacted
presumed LRT sputum mycobiota (as sputum passes the oral
cavity). In another study published by the same group the
antibiotic therapy of the same CF cohort was described in
more detail. Investigated CF patients were under continuous
treatment of antibiotics by inhalation applied twice a day at
home (mostly colistin or tobramycin according to clinical
needs). Interestingly, none of the patients received antibiotics
intravenously during the 2-years time frame of study (Kramer
et al., 2015b). Information on antimycotic therapy during or
prior to sampling was not provided. Even if the CF cohort
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represented routine clinical cases conclusions from mycobiota
(and microbiota) analysis can hardly be drawn based on
the missing information regarding antifungal therapy and
the incomplete description of inhalative antibiotic therapy
(how many patients received which inhalative antibacterial
medication?).
MYCOBIOME OF PATIENTS WITH
ASTHMA BRONCHIALE
Lower respiratory tract mycobiota were investigated in 30 asthma
patients and compared to 13 controls (van Woerden et al.,
2011, 2013). Patients were free of oral steroid use ≥2 weeks
prior to induced sputum sampling but most of them were on
inhaled corticosteroids. No information regarding previous or
current antibiotic or antifungal therapy was provided. After
nebulizing isotonic saline induced sputum was coughed into
petri dishes and spread on microscopic slides for microscopic
examination. Afterward a 5 mm2 area was subsequently excised
from the slide for DNA extraction and PCR. The excised
samples from each study group were combined to yield two
pooled samples, one from all asthma patient sputum samples
and one from all healthy control subject sputum samples.
Unfortunately, as described by the authors, a sample from
one asthma patient was inadvertently included in the control
set. Primer pairs Euk1a and Euk516r were used for PCR,
sequenced using a 454 pyrosequencer and DNA sequences
compared to SILVA database (van Woerden et al., 2013). In
total 136 fungal species were identified, with Psathyrella and
Malassezia spp. representing each approximately 25% of all
reads in asthma patients and Eremothecium spp. representing
approximately 40% of all reads in healthy controls. As the
authors noted in their discussion pooling sputum samples
prevented clear interpretation of results as fungi identified
could origin from one individual heavily colonized or from
several individuals colonized with identical or nearly similar
fungal species. In addition, oral mycobiota as well as material
used for sampling (petri dishes, slides, and saline) and its
impact on mycobiota results by potential contamination was
not investigated. Considering fungal species found in asthma
patients the pathophysiological role of Psathyrella candolleana,
a mushroom found on lawns or pastures in Europe and North
America, is unknown as well as the role of Eremothecium
sinecaudum, a yeast with pathogenic properties for plants,
in healthy subjects. The duration for collection of pooled
sputum and time intervals between sample collection and
storage was not provided as well as storing conditions. It has
been shown that prolonged time between sample collection
and sample storage (more than 12 h) as well as more
than four freeze thaw cycles distorted microbiota profiles
(Cuthbertson et al., 2014, 2015). As mentioned above, fungi
found in sputum from asthma patients and healthy controls
mainly contained environmental fungi present in plants and
grassland (van Woerden et al., 2013). Thus contamination of
the pooled sputum from both study groups during sampling
and storage cannot be ruled out. As sputum samples were
mixed up from individual patients and the pooled control
sample included one asthma sample interpretation of results and
considerations of differences between study populations is very
limited.
MYCOBIOME OF PATIENTS WITH LUNG
TRANSPLANTS
Mycobiota based on ITS-sequencing of 21 lung transplant
patients were investigated in BAL and oropharyngeal washes
and compared to healthy controls, the latter undergoing
a two-bronchoscope sampling technique or conventional
bronchoscopy (number of healthy controls undergoing each
of the sampling techniques was not provided in the text; in
figures within the manuscript data from six healthy controls
were shown). Two patients undergoing routine bronchoscopy
for evaluation of sarcoidosis and a lung nodule representing
adenocarcinoma (but both without lung transplantation)
were also included, but they were not further characterized
(Charlson et al., 2012). All lung transplant patients had
immunosuppressive and antibiotic therapy, three received
voriconazole and six nystatin (one patient had both antifungals).
Prior to bronchoscopy instruments were flushed with 10 ml
saline to investigate microbial DNA present in bronchoscopes
and saline. Fungal populations in lung transplant patients
were typically dominated by Candida in oral washes and
BAL and by Aspergillus in BAL but not in oral washes.
Oral washes of lung transplant patients revealed 13 samples
with high fungal sequences, all but one were dominated
by Candida. Patients without Candida in BAL had no (six
patients) or low (two patients) Candida sequences in oral
washes. As eight lung transplant patients had nystatin and/or
voriconazole therapy the presence or absence of Candida
and other fungi (targeted by nystatin and voriconazole) in
oral washes and BAL is hard to assess. Nystatin did not
consistently decrease or eliminate Candida from oral washes
but patients on voriconazole had no Candida sequences
in BAL (patient no. 34 was only presented in Figure E2,
supplementary material of the article; Charlson et al., 2012).
However, in two of voriconazole treated patients Aspergillus
sequences were detected (patient no. 34, also with positive
Aspergillus culture, and patient no. 43). One patient (no.
36) had Aspergillus in culture and in mycobiota analysis but
in a second BAL 2 months later Aspergillus was no longer
detected by both methods while the patient was treated with
voriconazole; voriconazole obviously eliminated Aspergillus in
that particular patient. Candida was absent in BAL of healthy
volunteers although Candida was present in oral washes.
Unfortunately no information regarding a potential pathogenetic
role of fungi detected within mycobiota was provided for the
presented lung transplant patients. The presence or absence of
invasive fungal infection or fungal breakthrough infection in
voriconazole treated patients (based on clinical data, radiological
examination, biomarkers like galactomannan or 1,3-beta-D-
glucan testing, voriconazole trough level) and outcome was not
mentioned.
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MYCOBIOTA IN MISCELLANEOUS
PULMONARY DISEASES AND HIV
POSITIVE PATIENTS
In a study published by the same authors as mentioned above in
the lung transplant patients, data from an almost similar study
cohort included mycobiota from 42 lung transplant patients,
19 HIV positive patients, 13 patients with various pulmonary
diseases and 12 healthy controls (Bittinger et al., 2014). Four
control patients were counted twice as they were investigated
by a double bronchoscopy and single bronchoscopy technique
at least 1 year apart. Healthy and HIV positive subjects were
described not to have respiratory symptoms and antibiotic
therapy. However, in the Table 1 one HIV patient did in fact
have antibiotic therapy (clindamycin within 3 months prior
to sampling) and another one had inhalative corticosteroid
treatment. Subjects within the healthy and HIV positive study
groups where smokers and non-smokers. In patients with
various pulmonary diseases two patients had immunosuppressive
therapy, two had systemic antibiotic therapy but two patients
with pneumonia surprisingly had no antibiotic therapy. Two
out of 24 lung transplant patients refused collection of clinical
data. Thirteen of the remaining 22 lung transplant patients had
antifungal therapy (11 nystatin, two voriconazole treatments).
Twenty received antibiotic therapy (mainly trimethoprim and
sulfamethoxazole), two had atovaquone therapy and all received
immunosuppressants (presented in Supplementary Table S3 of
Bittinger et al., 2014). The authors also focused on analysis of
possible confounding factors as 132 samples from laboratory
water, bronchoscope canal flushes, saline used for oral washes
and BAL, sterile swabs and lab tabletop surface were investigated
[supplemental report in (Bittinger et al., 2014)]. Interestingly, the
composition of fungi in BAL samples was generally similar to
that in contamination controls. After correction of abundance by
subtraction of reads found in the control samples (e.g., saline)
Candida was mainly found in BAL and oral washes of the
study groups (Figure 37–43 in supplemental report of Bittinger
et al., 2014) as well as Aspergillus and Cladosporium in lung
transplant patients and those with miscellaneous pulmonary
diseases (Figure 37 and 38 in supplementary report of Bittinger
et al., 2014). Clinical significance of fungal detection in presented
patient groups is unclear from that study as clinical data including
radiological examination, biomarkers, introduction of antifungal
treatment and outcome have not been reported.
Another study provided mycobiota data from 32 HIV positive
(10 with COPD) and 24 HIV-uninfected patients extracted
from a cohort comprising 396 HIV-infected and HIV-uninfected
individuals with smokers and marijuana abusers in both study
groups (Cui et al., 2015). Prior to sampling study subjects
had stable respiratory symptoms in previous 4 weeks and
did not receive antibiotic or immunosuppressive therapy in
previous 6 months. Oral wash, induced sputum (<30% squamous
cell count) and BAL passing the oral cavity were collected
TABLE 1 | Overview of studies investigating LRT mycobiota.
Study author, year of
publication
Patients (pts)/study subjects
(controls)
Sampling method Material analyzed
Delhaes et al., 2012 four CF pts sputum expectoration sputum
Willger et al., 2014 six CF pts sputum expectoration sputum
Kramer et al., 2015a 56 CF pts sputum expectoration sputum
van Woerden et al., 2013
van Woerden et al., 2011
30 asthma bronchiale pts
13 controls
induced sputum expectoration two pooled sputum samples (one from
patients and one from controls)
Charlson et al., 2012 21 lung transplant pts
one patient with suspected sarcoidosis
one patient with adenocarcinoma
bronchoscopy (including 2-bronchoscope
sampling in healthy controls)
oral washes with saline
bronchoscope saline flush
BAL
Oral washes
saline and bronchoscope flush
six controls
Bittinger et al., 2014 42 lung transplant pts
19 HIV pts
13 pts with various pulmonary diseases
12 controls
bronchoscopy (including 2-bronchoscope
sampling in healthy controls)
oral washes with saline
bronchoscope saline flush
swabs
BAL
oral washes
laboratory water
bronchoscope flushes
saline
sterile swabs
lab tabletop surface
Cui et al., 2015 32 HIV pts [10 with chronic obstructive
pulmonary disease (COPD)]
24 HIV negative pts
oral washes with saline
induced sputum
bronchoscopy
oral washes
sputum
BAL
Bousbia et al., 2012 160 ICU pts with pneumonia
25 ICU pts without pneumonia
bronchoscopy BAL
Krause et al., 2016 39 ICU pts
seven non-ICU patients with antibiotic
therapy
five ICU pts for sampling comparison
eight controls
bronchoscopy through endotracheal tubes
suction of endobronchial secretion through
endotracheal tubes
bronchoscope saline flush
BAL
endobronchial secretion
bronchoscope flushes
saline
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as well as control samples by aspirating saline through the
bronchoscope channel. Fungal microbiota were analyzed by
sequencing amplicons generated by PCR using ITS- and 18S-
targeting primers. 18S data were used for operational taxonomic
unit (OTU)-type analysis and ITS data were used for species-
level analysis. The authors mentioned that the 18S rRNA gene
gave higher PCR-positive rates, but fewer fungal reads compared
with the ITS, because the 18S primers cross-reacted with host
(=human); consequently, approximately 90% of the raw 18S
sequencing reads were human. By using 18S data for comparison
of different sampling techniques, the authors interestingly found
that induced sputum shared little similarity with BAL. In
principle coordinate analysis of 18S data of healthy subjects
(HIV negative, normal lung function) using only 30% of all
data, BAL samples clustered together with oral wash, induced
sputum overlapped in part with oral wash samples but not with
BAL. A similar distribution pattern was seen with the entire
cohort including HIV-infected and HIV-uninfected individuals
with or without normal lung function. Candida represented
more than 90% of the ITS reads and was clearly dominant
in oral washes compared with BAL. There was also a higher
prevalence of Candida in induced sputum compared with BAL.
Ceriporia lacerata, Saccharomyces cerevisiae, and Penicillium
brevicompactum were predominant in BAL compared to oral
wash. None of these species were detected in the corresponding
bronchoscopic control samples, indicating that environmental
contamination was unlikely. In HIV infected individuals nine
species including Pneumocystis jirovecii (confirmed by nested
PCR) were overrepresented in BAL compared to HIV-uninfected
individuals. No species was associated with COPD in the HIV-
infected cohort as compared with HIV-infected individuals with
normal lung function. In marijuana smokers, with and without
HIV infection, four species (including two that are known plant
pathogens, Phialocephala virens and Taphrina tormentillae) were
overrepresented as compared with individuals who had not
smoked marijuana in the year prior to sampling. The authors
mentioned that smoking marijuana without filters might have
contributed to inhalation of this certain environmental/plant
fungi. Considering all subjects investigated, fungal communities
in the LRT resembled those in the mouth. This result could be
caused by microaspiration of oral content, contamination during
bronchoscopy when passing the oral cavity, contamination of
induced sputum with oral microbiota or contamination of oral
microbiota by coughing or exhalation. The latter is unlikely
as oral wash was collected prior to sputum sampling or
bronchoscopy.
MYCOBIOME IN LRT OF ICU PATIENTS
Mycobiota in LRT of ICU patients were investigated in two
studies. In the first study 18S rRNA gene sequencing was
performed to analyze the etiology of pneumonia in ICU patients
with community acquired pneumonia (CAP, 32 episodes),
ventilator-associated pneumonia (VAP, 106 episodes), non-
ventilator ICU pneumonia (NV-ICU P, 22 episodes), aspiration
pneumonia (AP, 25 episodes) and compared to 25 ICU patients
without pneumonia (CS; Bousbia et al., 2012). As pneumonia
cases were counted as episodes (185 pneumonia episodes) the
total number of patients included in each of the pneumonia
subgroups is not clear. However, in some tables the number
of pneumonia patients were 185 enabling the conclusion that
one pneumonia episode obviously corresponded to one patient.
Clinical data regarding underlying diseases beside pneumonia,
(previous) antibiotic and antimycotic therapy or initiation of
new antiinfective therapy, presence or absence of tracheal tubes,
invasive or non-invasive mechanical ventilation and underlying
diseases were not provided. Detailed sampling procedures,
e.g., time of BAL sampling after admission or diagnosis or
pneumonia, BAL by bronchoscopy passing the oral cavity
or through oropharyngeal ventilation tubes, transport and
storage of BAL cultures, investigation of material used for
BAL, investigation of pre-BAL bronchoscopy flushes were not
mentioned. Interestingly, ICU patients used as control patients
(=no pneumonia) also had ARDS but with comparable or
even higher numbers compared to some pneumonia patients
(38% in CAP, 33% in VAP, 41% in NV-ICU P, 12% in AP;
31% in all pneumonia patients and 28% in patients without
pneumonia considered as controls). The proportion of patients
with immunosuppressive therapy in each pneumonia group was
reported but the type of immunosuppressive therapy was not
provided (38% in CAP, 40% in VAP, 50% in NV-ICU P, 36% in AP;
40% in all pneumonia patients and 16% in controls). C. albicans
signatures were most abundant in all patients groups and
controls.C. utilis showed higher abundance in controls compared
to pneumonia subgroups (p = 0.01; Supplementary Table S5
in supplementary material of Bousbia et al., 2012). Aspergillus,
Penicillium and Cladophialophora genera were dominant in the
CAP cohort but did not reach significant differences compared
to other cohorts. Tremellomycetes (represented by Cryptococcus)
was identified in NV-ICU P, whereas Agaricomycetes and
unclassified Ascomycota were only identified in VAP patients.
Sordariomycetes were only identified in controls. However,
maybe based on small numbers, no significant difference
could be calculated for these classes. Beside bacterial and
fungal microbiome analysis the authors included a lot of
other microbiological methods to detect microorganisms causing
pneumonia. For many of detected microorganisms including
those found in mycobiota analysis the authors raised the question
on the actual role of these microorganisms in pneumonia. The
authors concluded that the respiratory microbiota was more
complex than expected (Bousbia et al., 2012).
In another study, LRT mycobiota in non-neutropenic
intubated and mechanically ventilated ICU patients with
antibiotic therapy to treat pneumonia were investigated and
compared to several other groups: healthy controls without
preceding antibiotic therapy, patients without pulmonary
diseases with antibiotic therapy, non-neutropenic intubated
and mechanically ventilated ICU patients without preceding
or current antibiotic therapy, non-neutropenic intubated and
mechanically ventilated ICU patients without pulmonary disease
but with antibiotic therapy for treatment of extrapulmonary
infection. Smoking behavior of study patients was not evaluated.
All study subjects were without antimycotic treatment ≥8 weeks
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prior to sampling (Krause et al., 2016). LRT in all patients and
healthy study subjects were sampled through endotracheal tubes
avoiding contact to the oral cavity. Non-ICU patients and healthy
controls were sampled by aspiration of endobronchial secretion
and ICU patients were sampled by bronchoscopic guided BAL.
Saline used for BAL and collected after flushing the sampling
channel of the bronchoscope immediately before bronchoscopy
was also investigated. Sampling techniques (endobronchial
secretion versus BAL) showed similar results and saline did not
influence mycobiota results. The results showed that Candida
was part of the fungal microbiota of various intubated and
mechanically ventilated ICU patients with and without antibiotic
therapy and with and without pneumonia (59–73% Candida
signatures within 5–8 fungal genera; Krause et al., 2016).
Candida sequences were not present in mycobiota of non-ICU
patients with antibiotic therapy and healthy controls. Admission
to and treatment on ICUs shifted LRT fungal microbiota to
Candida spp. dominated fungal profiles but antibiotic therapy
did not. Mycobiota analysis was not done with samples from
the oral cavity but in conventional cultures antibiotic therapy
increased the prevalence of Candida spp. in this compartment.
Conventional cultures also showed that admission to the ICU
increased the prevalence of Candida spp. in the LRT, but other
fungi were not detected by culture. None of the ICU patients
had candidemia or other invasive fungal disease as determined by
clinical, imaging, laboratory and microbiological investigations.
DISCUSSION
The mycobiota in the LRT is diverse and varies in different
populations and LRT diseases. Links to certain stages of
diseases or LRT dysfunction have been proposed. In one
study the diversity and species richness of fungal and bacterial
communities were significantly lower in patients with decreased
lung function as assessed by forced expiratory pressure in 1 s in
lung function tests (Delhaes et al., 2012). However, the association
was mainly derived from two patients with preceding antibiotic
therapy and antifungal therapy and the contribution of fungal or
bacterial microbiota to lung function could not be distinguished.
Despite variable fungal composition in LRT, Candida overall
dominated mycobiota in most of the studies including CF
patients, lung transplant patients, HIV infected patients and ICU
patients (Bousbia et al., 2012; Charlson et al., 2012; Bittinger
et al., 2014; Willger et al., 2014; Cui et al., 2015; Kramer et al.,
2015a; Krause et al., 2016). In remaining studies with dominating
fungi other than Candida methodologies were too weak to draw
profound conclusions. However, Candida was also the most
abundant genus in oral mycobiome analysis (Ghannoum et al.,
2010) questioning the results of studies that presented sputum
samples without quality control (e.g., <10 squamous cells in
high power field sputum examination). Unfortunately, even in
bronchoscopy guided BAL contact to oral mucosa or saliva
during insertion of the bronchoscope might alter microbiota
composition of BAL obtained through orally contaminated
bronchoscopy tips. But LRT mycobiota similar or close to
oral mycobiota does not necessarily represent contamination of
bronchoscopes or translocation of mycobiota by bronchoscopy,
as upper and LRT might be colonized by identical or closely
related microorganisms. Similar or close mycobiota in upper and
LRT analysis could also be caused by microaspiration of oral
content, contamination of induced sputum with oral microbiota
or contamination of oral microbiota by coughing or exhalation.
To overcome limitations in interpreting mycobiota data sampling
techniques bypassing the oral cavity (e.g., via endotracheal tubes)
or two-bronchoscopy sampling techniques should therefore
be preferred to obtain true LRT samples. By applying such
techniques and therefore exclusion of contamination, mycobiota
in upper and LRT could be assessed more reliable.
In two previous studies reagents (e.g., saline, lab water, lab
surfaces) have been analyzed to assess its influence on microbiota
results from BAL (Bittinger et al., 2014; Krause et al., 2016);
however, in other studies this was not done (Erb-Downward et al.,
2011; van Woerden et al., 2011, 2013). Nevertheless, none of the
studies investigating reagents showed that Candida abundance
reached >50% as has been found in BAL samples from ICU
patients (Krause et al., 2016). The reason for the elevated Candida
abundance in LRT of ICU patients is not clear. The role of ICU
environment or translocation of microorganisms from intestinal
mycobiota (via ICU personnel or retrograde translocation up to
the oral cavity followed by microaspiration passing the cuff or the
orotracheal tube) in elevated LRT Candida abundance or in shifts
of LRT mycobiota has not been investigated yet.
Three studies included sequential sampling for assessment
of dynamics in mycobiota composition over time. Observation
periods varied between days (ICU patients; Krause et al., 2016),
weeks (CF patients; Willger et al., 2014), 3 months to 1 year
(CF patients; Delhaes et al., 2012), and months up to 2 years
(CF patients; Kramer et al., 2015a). Conclusions are difficult to
draw based on low numbers of individuals investigated, different
patient groups and differences in time frames elapsing between
sampling. Whereas high intraindividual differences with changes
inCandida abundance were found in one CF study (Delhaes et al.,
2012) another CF study found stable results (Willger et al., 2014).
The third CF study found differences in number of fungal genera
in some patients providing two sputum samples (Kramer et al.,
2015a). In ICU patients fungal microbiota were stable in 3 of 4
patients as shown by analysis of first and second BAL sample 4 to
7 days apart (Krause et al., 2016). Two studies compared different
LRT sampling techniques in individual patients, i.e., induced
sputum and BAL in one study (Cui et al., 2015) and endotracheal
aspiration and BAL in another study (Krause et al., 2016).
Whereas differences were detected between sputum and BAL
based on 18S rRNA sequencing no difference was found between
endotracheal aspirate and BAL based on ITS sequencing. As the
authors mentioned in 18S based sequencing human 18S rRNA
reads reduced the sequencing depth of fungal 18S rRNA gene
reads, which might have influenced comparative data analysis of
sputum and BAL. Although some studies included conventional
cultures for assessment of microbial composition all studies
mentioned above did not account for viability of microbiota
explored by sequencing methods. Therefore it is almost unknown
if detected mycobiota represent true alive residential or inhaled
dead microorganisms or both. Future studies need to include this
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aspect by e.g., dividing samples and treating of one half with
propidium monoazide (PMA) to select for dead cells (Nocker
et al., 2007).
The role of Candida in LRT in above mentioned diseases
and conditions is still largely unknown. Patient characteristics
provided in some mycobiota studies prohibit clinical conclusions
as relevant data regarding underlying diseases, presence or
absence of LRT infectious disease, initiation of antibiotic or
antimycotic therapy, and outcome (e.g., invasive fungal infection)
are missing. In the study investigating asthma bronchiale patients
no information regarding previous or current antibiotic or
antifungal therapy was provided (van Woerden et al., 2013). As
shown in one of the studies in ICU patients (Krause et al., 2016)
antibiotic therapy surprisingly did not influence mycobiota.
Interestingly, antibiotic therapy in CF patients overall also had no
impact on mycobiota composition and fungal burden although
fungal burden varied between individual patients with decreasing
and increasing levels (Willger et al., 2014). The influence of
antimycotic therapy on LRT mycobiota is still unclear but some
antimycotics might alter LRT mycobiota as detected in one
patient in the lung transplant patient group discussed above
(Charlson et al., 2012).
CONCLUSION
Although some studies suggest renewal of our pathophysiological
understanding of mycobiota in LRT, shortcomings in clinically
relevant methodologies in some studies call for further
investigations to compensate previous deficiencies. Improved
study settings will allow to draw better clinically relevant
conclusions regarding diagnostic or therapeutic procedures in
certain LRT diseases. As previously suggested, future mycobiota
(and bacterial microbiota) studies should enable to answer one
or more of the following questions: Can experiments detect
differences that matter (in the context of disease and treatment)?
Does the study show causation or just correlation? What is
the mechanism? How much do experiments reflect reality?
Could anything else explain the results? (Hanage, 2014). To
obtain clinically relevant answers efforts should be enhanced
to collect well characterized and described patient groups as
well as healthy individuals for comparative data analysis and
to apply thorough sampling techniques. For clinical routine
we learn from current stage of knowledge that conventional
microbiology obviously does not reflect true composition of
LRT mycobiome. However, therapeutic studies based on new
sequencing techniques are missing. We need to proceed with
elucidation of the role of mycobiota in healthy LRT and
LRT diseases to hopefully improve patient care. This might
include diagnostic procedures with cultivation-independent
molecular assays and prophylactic as well as therapeutic
interventions in patients potentially suffering from mycobiota
alterations (e.g., CF patients, lung transplant patients, ICU
patients).
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